title: Evaluation of interleukin 12 and CD56+ lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease.
abstract: The present study tried to explain CD56+ lymphocyte cells activities and possible prognostic role of these cells in Graft-Versus-Host-Disease (GVHD). The role of IL-12 activation and function is of interest in this study. Peripheral blood samples of 51 Hematopoietic Stem Cell Transplantation (HSCT) recipients collected at before (day -8) and after (days 7 and 14). PBMC were collected by Ficoll separation and analyzed by Flow Cytometry using triple antibody (CD45-PerCP, CD56-FITC, and CD69-PE staining and control antibody. Levels of the cytokine IL-12 in the patient's serum were evaluated by ELISA. Percentage of CD56+ lymphocytes (CD56+bright) cells was significantly increased at day 14 in patients with acute GVHD and percentage of lymphocytes expressing CD69 was significantly increased at days 7 and 14 posts HSCT in patients with acute GVHD in comparison to those in non-GVHD patients. Baseline serum IL-12 levels (pre-HSCT, day -8) were significantly higher in those HSCT recipients who did not develop GVHD. This study showed that post-transplant CD56+ lymphocytes and pre-transplant serum levels of IL-12 play significant roles in the induction of and protection against GVHD, respectively. The increase in the percentage of CD69+ cells indicates the activation of lymphocyte in acute GVHD group.
authors.affiliation: Cancer Research Center, Dept. of Immunology, Semnan University of Medical Sciences, Semnan, Iran.
authors.forename: Raziyeh
authors.initials: R
authors.lastname: Tootoonchian
authors.affiliation: Cancer Research Center, Dept. of Immunology, Semnan University of Medical Sciences, Semnan, Iran.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Pak
authors.affiliation: Iran National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
authors.forename: Ali M
authors.initials: AM
authors.lastname: Ardekani
authors.affiliation: Cancer Research Center, Dept. of Immunology, Semnan University of Medical Sciences, Semnan, Iran.
authors.forename: Nasrin
authors.initials: N
authors.lastname: Sehati
authors.affiliation: Experimental Cancer Medicine (ECM), Clinical Research Center (KFC), Novum, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Manuchehr
authors.initials: M
authors.lastname: Abedi-Valugerdi
authors.affiliation: Cancer Research Center, Dept. of Immunology, Semnan University of Medical Sciences, Semnan, Iran; Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden. Electronic address: parviz.kokhai@ki.se.
authors.forename: Parviz
authors.initials: P
authors.lastname: Kokhaei
mesh_terms: D000208:Acute Disease; D015703:Antigens, CD / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D002452:Cell Count; D002469:Cell Separation; D002648:Child; D042241:Early Diagnosis; D005260:Female; D005434:Flow Cytometry; D006086:Graft vs Host Disease / Q000175:diagnosis*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D018664:Interleukin-12 / Q000097:blood*; D037181:Lectins, C-Type / Q000378:metabolism; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D011379:Prognosis; D000099192:CD69 Antigens
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019002:CD56 Antigen; D018664:Interleukin-12; D037181:Lectins, C-Type; D000099192:CD69 Antigens
keywords: CD56+ lymphocyte; GVHD; IL-12